PlasmaTech Biopharmaceuticals

Plasmatech Biopharmaceuticals to acquire Abeona Therapeutics

Friday, May 8, 2015

PlasmaTech Biopharmaceuticals, a Texas-based biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, has entered into a definitive agreement to acquire Abeona Therapeutics, a company engaged in the development and commercialization of therapies for patients with lysosomal storage diseases. The company will issue to Abeona Therapeutic members a total of 3,979,761 common shares upon closing of the transaction, and up to an additional $9 million in performance milestones, in common stock or cash, at the company’s option.

[Read More]

Stephen T. Sonis joins PlasmaTech Biopharmaceuticals’ scientific advisory board

Friday, November 7, 2014

PlasmaTech Biopharmaceuticals, a biopharmaceutical company advancing patient care in critical areas, has announced that Stephen T. Sonis, DMD, DMSc, has joined its scientific advisory board (SAB). A world-renowned expert in the clinical treatment and research of cancer-related mucosal toxicities, Sonis has collaborated with management in recent years on advancing the company’s clinical efforts of its oral mucositis treatment, MuGard.

[Read More]